Effects of a controlled-release cisplatin delivery system used after resection of mammary carcinoma in mice
Ehrhart, N.; Dernell, W.S.; Ehrhart, E.J.; Hutchison, J.M.; Douple, E.B.; Brekke, J.H.; Straw, R.C.; Withrow, S.J.
American Journal of Veterinary Research 60(11): 1347-1351
1999
ISSN/ISBN: 0002-9645 PMID: 10566806 Document Number: 502022
42 female C3H-HeJ mice were inoculated with mammary carcinoma cells. Between 2 and 6 days later, tumours were marginally resected and mice were assigned to 1 of 3 groups: no treatment (control; 14 mice), cisplatin administered intraperitoneally (IP cisplatin; 14), and cisplatin delivered by use of an open-cell polylactic acid system placed within the tumour bed (slow-release cisplatin; 14 mice). Tumour re-growth was measured daily. Mice were killed 14 days after surgery and complete necropsies were performed. Tumour re-growth was not detected in the slow-release cisplatin group; however, tumour re-growth was detected in 7 of 14 mice in the IP cisplatin group and 14 of 14 mice in the control group. Median number of days to tumour re-growth was 13.5+or-0.64 and 7.79+or-0.87 in the IP cisplatin and control groups, respectively. Mice in the IP cisplatin group had significantly delayed tumour re-growth, compared with control mice. Metastases to lungs were detected in 8 of 14 control mice but were not detected in mice in either cisplatin treatment group. The open-cell polylactic acid with cisplatin delivery system was successful in delaying local tumour re-growth and metastasis in mice with marginally resected mammary carcinoma. It is concluded that the use of a controlled-release cisplatin delivery system may be an effective adjunct treatment following excision of mammary carcinoma in humans and other animals.